RDX 022

Drug Profile

RDX 022

Alternative Names: RDX 227675; RDX 7675; RDX022

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ardelyx
  • Class Cardiovascular therapies; Polymers; Polystyrenes
  • Mechanism of Action Binding agents; Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperkalaemia

Most Recent Events

  • 03 Jan 2017 Phase-III clinical trials in Hyperkalaemia in USA (PO)
  • 03 Jan 2017 Ardelyx initiates enrolment in a phase IIb trial for Hyperkalaemia in USA
  • 01 Jan 2017 Ardelyx initiates a phase II trial for Hyperkalaemia in USA (PO) (NCT03018067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top